IceCure Medical’s ProSense boosts immune response against cancer in study

IceCure Medical announced the publication of a study titled “Piezo1 facilitates optimal T cell activation during tumor challenge” in the highly influential peer-reviewed journal OncoImmunology. The study, conducted at Case Western Reserve University School of Medicine in Cleveland, Ohio, by Muta Abiff et al, utilized ProSense for cryoablation procedures in a mouse model to explore the role of the Piezo1 protein in regulating T-cell tumor immune-mediated rejection of soft tissue tumors. The Piezo1 study involved performing cryoablation with ProSense on tumor volumes of approximately 100mm3 (diameter ~6 mm) using a mouse model. The cryoprobe was placed percutaneously directly on the tumor mass. The data demonstrates that cryoablation induces immune rejection by enhancing CD8+ T cell activation, a process dependent on T cell expression of Piezo1. Increased activation and responsiveness, potentially leading to a more robust immune response against abnormal cells, was detected up to 2 weeks after cryoablation, displayed as an increase in CD25 and interferon gamma expression on CD8+ T cells.